ELISA Kit for Endothelial NOS (eNOS)
NOS3; ECNOS; NOS III; E-NOS; C-NOS; ENOS; CNOS; Constitutive NOS; Nitric Oxide Synthase 3, Endothelial
- Product No.SEA868Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range0.156-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.057ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
For more details, please contact local distributors! US$ 630
For more details, please contact local distributors! US$ 2835
For more details, please contact local distributors! US$ 5355
For more details, please contact local distributors! US$ 44100
For more details, please contact local distributors!
This assay has high sensitivity and excellent specificity for detection of Endothelial NOS (eNOS).
No significant cross-reactivity or interference between Endothelial NOS (eNOS) and analogues was observed.
Matrices listed below were spiked with certain level of recombinant Endothelial NOS (eNOS) and the recovery rates were calculated by comparing the measured value to the expected amount of Endothelial NOS (eNOS) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Endothelial NOS (eNOS) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Endothelial NOS (eNOS) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Endothelial NOS (eNOS) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|TMB Substrate||1×9mL||Stop Solution||1×6mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
|Journal of Ethnopharmacology||Impact of matrine on inflammation related factors in rat intestinal microvascular endothelial cells ScienceDirect: S0378874109004541|
|PLoS One||A Novel Mechanism of Formaldehyde Neurotoxicity: Inhibition of Hydrogen Sulfide Generation by Promoting Overproduction of Nitric Oxide PubMed: 23359814|
|6th International Scientific Interdisciplinary Conference (ISIC)||Inflammation influence on the formation of endothelial dysfunction in hypertensive patients caused by obesity Knmu: Source|
|PLoS One.||SIRT1 Gene Polymorphisms Affect the Protein Expression in Cardiovascular Diseases Plos: Source|
|INTERNATIONAL JOURNAL OF MEDICINE AND MEDICAL RESEARCH||L-ARGININE, BUT NOT L-NAME PROTECTS AGAINST LIVER INJURY INDUCED BY EXPERIMENTAL ISCHEMIA-REPERFUSION Tdmu:Source|
|Journal of Clinical Laboratory Analysis||Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome Pubmed:24798146|
|Endocrine||Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia Pubmed:24840719|
|PLOS ONE||A Remarkable Age-Related Increase in SIRT1 Protein Expression against Oxidative Stress in Elderly: PubMed: 25785999|
|J Trace Elem Med Biol||Comparative angioprotective effects of magnesium compounds PubMed: 25127069|
|Journal of Functional Foods||Peptides from hydrolysate of lantern fish (Benthosema pterotum) proved neuroprotective in vitro and in vivo science:S1756464616300639|
|Медицина и здравоохранение||Роль индуцибельной NO-синтазы в механизмах регуляции функциональной активности кальций-активируемых калиевых каналов коронарных сосудов у крыс, адаптированных к стрессу article:n|
|journal of molecular and cellular cardiology||Mutant DD genotype of NFKB1 gene is associated with the susceptibility and severity of coronary artery disease. pubmed:28088561|
|International Journal of Medicine and Medical Research||ThE REmOdELINg Of LEfT ATRIUm ANd vAsOdILATION fAcTORs chANgEs IN IschEmIc hEART fAILURE 7038|
|International Journal of Ophthalmology||Endothelial nitric oxide synthase deficiency influences normal cell cycle progression andapoptosis in trabecular meshwork cells. pubmed:27366677|
|Biomed Pharmacother.||SIRT1 inhibits releases of HMGB1 and HSP70 from human umbilical vein endothelial cells caused by IL-6 and the serum from a preeclampsia patient and protects the cells from death. pubmed:28122311|
|Biomedicine & Pharmacotherapy||SIRT1 inhibits releases of HMGB1 and HSP70 from human umbilical vein endothelial cells caused by IL-6 and the serum from a preeclampsia patient and protects the cells from death DOI:10.1016/j.biopha.2017.01.087|
|Asian Journal of Science and Technology||THE INFLUENCE OF THE ADDITIONAL USAGE OF L-ARGININE ON THE FACTORS OF VASODILATION AND THE CLINICAL DATA, COMPLICATED WITH CARDIAC DECOMPENSATION WITH REDUCED AND PRESERVED FRACTURE OF THE LEFT VENTRICLE THAT PATIENTS WITH STABLE CORONARY HEART DISEASE HAVE ISSN: 0976-3376|
|Catalog No.||Related products for research use of Homo sapiens (Human) Organism species||Applications (RESEARCH USE ONLY!)|
|RPA868Hu03||Recombinant Endothelial NOS (eNOS)||Positive Control; Immunogen; SDS-PAGE; WB.|
|RPA868Hu04||Recombinant Endothelial NOS (eNOS)||Positive Control; Immunogen; SDS-PAGE; WB.|
|RPA868Hu01||Recombinant Endothelial NOS (eNOS)||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAA868Hu04||Polyclonal Antibody to Endothelial NOS (eNOS)||WB; IHC; ICC; IP.|
|PAA868Hu03||Polyclonal Antibody to Endothelial NOS (eNOS)||WB; IHC; ICC; IP.|
|PAA868Hu01||Polyclonal Antibody to Endothelial NOS (eNOS)||WB; IHC; ICC; IP.|
|LAA868Hu71||Biotin-Linked Polyclonal Antibody to Endothelial NOS (eNOS)||WB; IHC; ICC.|
|MAA868Hu22||Monoclonal Antibody to Endothelial NOS (eNOS)||WB; IHC; ICC; IP.|
|SEA868Hu||ELISA Kit for Endothelial NOS (eNOS)||Enzyme-linked immunosorbent assay for Antigen Detection.|